Zobrazeno 1 - 10
of 86
pro vyhledávání: '"William H Bisson"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/0da2a6bbb9a141999eddea2b1fe8d345
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The complexity of cancer requires a comprehensive approach to understand its diverse manifestations and underlying mechanisms. Initially outlined by Hanahan and Weinberg in 2000 and updated in 2010, the hallmarks of cancer provide a conceptual basis
Externí odkaz:
https://doaj.org/article/0f5b618b396741ca8f63a1536ae70157
Autor:
Britton C Goodale, Jane K La Du, William H Bisson, Derek B Janszen, Katrina M Waters, Robert L Tanguay
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e29346 (2012)
The aryl hydrocarbon receptor (AHR) is well known for mediating the toxic effects of TCDD and has been a subject of intense research for over 30 years. Current investigations continue to uncover its endogenous and regulatory roles in a wide variety o
Externí odkaz:
https://doaj.org/article/c8fa8fc591df487a9bb319ce0a0c31cc
Autor:
Edmond F O'Donnell, Katerine S Saili, Daniel C Koch, Prasad R Kopparapu, David Farrer, William H Bisson, Lijoy K Mathew, Sumitra Sengupta, Nancy I Kerkvliet, Robert L Tanguay, Siva Kumar Kolluri
Publikováno v:
PLoS ONE, Vol 5, Iss 10 (2010)
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates the toxicity and biological activity of dioxins and related chemicals. The AhR influences a variety of processes involved in cellular growth and differentiat
Externí odkaz:
https://doaj.org/article/ff6d993d8c44450790b18bd377768fa9
Autor:
Luca Mologni, Sébastien Tardy, Alfonso Zambon, Alexandre Orsato, Cédric Schneider, William H. Bisson, Monica Ceccon, Michela Viltadi, David Goyard, Pierre Garcia, Joseph D’Attoma, Sara Pannilunghi, Vito Vece, Jerome Bertho, David Gueyrard, Peter Goekjian, Leonardo Scapozza, Carlo Gambacorti-Passerini
Publikováno v:
ACS Omega, Vol 7, Iss 25, Pp 22059-22060 (2022)
Externí odkaz:
https://doaj.org/article/06412c463a324452867b30b2e8ae1c45
Autor:
Lei G. Wang, Antonio R. Montaño, Jason R. Combs, Nathan P. McMahon, Allison Solanki, Michelle M. Gomes, Kai Tao, William H. Bisson, Dani A. Szafran, Kimberley S. Samkoe, Kenneth M. Tichauer, Summer L. Gibbs
Publikováno v:
Nature Chemistry. 15:729-739
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57f501ad9a14b3b3c289c415a284a8f1
https://doi.org/10.1038/s41557-023-01173-6
https://doi.org/10.1038/s41557-023-01173-6
Autor:
Lei G. Wang, Antonio R. Montaño, Jason R. Combs, Nathan P. McMahon, Allison Solanki, Michelle M. Gomes, Kai Tao, William H. Bisson, Dani A. Szafran, Kimberley S. Samkoe, Kenneth M. Tichauer, Summer L. Gibbs
Publikováno v:
Nature Chemistry. 15:740-740
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5def2caf307f694841d5ac2e9bf68179
https://doi.org/10.1038/s41557-023-01213-1
https://doi.org/10.1038/s41557-023-01213-1
Autor:
Luca Mologni, Sébastien Tardy, Alfonso Zambon, Alexandre Orsato, William H. Bisson, Monica Ceccon, Michela Viltadi, Joseph D’Attoma, Sara Pannilunghi, Vito Vece, Jerome Bertho, Peter Goekjian, Leonardo Scapozza, Carlo Gambacorti-Passerini
Publikováno v:
ACS omega. 7(20)
The anaplastic lymphoma kinase (ALK) is abnormally expressed and hyperactivated in a number of tumors and represents an ideal therapeutic target. Despite excellent clinical responses to ALK inhibition, drug resistance still represents an issue and no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a7b1e41703657ff1df592093720c15
https://pubmed.ncbi.nlm.nih.gov/35785321
https://pubmed.ncbi.nlm.nih.gov/35785321
Autor:
Luca Mologni, Alexandre Orsato, Alfonso Zambon, Sébastien Tardy, William H. Bisson, Cedric Schneider, Monica Ceccon, Michela Viltadi, Joseph D'Attoma, Sara Pannilunghi, Vito Vece, David Gueyrard, Jerome Bertho, Leonardo Scapozza, Peter Goekjian, Carlo Gambacorti-Passerini
The Anaplastic Lymphoma Kinase (ALK) is a therapeutic target for personalized medicine in selected cancers. Despite excellent clinical responses to ALK inhibitors, most patients develop drug resistance and relapse. New compounds with alternative bind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf89bd1c05f951a54aeeb8be0996d559
https://hdl.handle.net/11380/1278237
https://hdl.handle.net/11380/1278237
Autor:
Monika A. Davare, Daniel Bottomly, Sunil K. Joshi, Shannon K. McWeeney, Cristina E. Tognon, Brian J. Druker, Elie Traer, Jeffrey W. Tyner, Ariane Huang, William H. Bisson, Kevin Watanabe-Smith, Kristin Qian
Publikováno v:
Blood
Much of what is known about the neurotrophic receptor tyrosine kinase (NTRK) genes in cancer was revealed through identification and characterization of activating Trk fusions across many tumor types. A resurgence of interest in these receptors has e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf9432a8035cb39437a8fafbbfb3928e
https://europepmc.org/articles/PMC7290093/
https://europepmc.org/articles/PMC7290093/